Ensign Peak Advisors
BCYC

Ensign Peak Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Ensign Peak Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,033
Closed -$559K – 1831
2022
Q3 		$559K Buy
24,033
+5,773
+32% +$137K ﹤0.01% 1394
2022
Q2 		$306K Hold
18,260
– – ﹤0.01% 1672
2022
Q1 		$801K Hold
18,260
– – ﹤0.01% 1323
2021
Q4 		$1.11M Buy
+18,260
New +$1.01M ﹤0.01% 1219

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Ensign Peak Advisors's BCYC Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Bicycle Therapeutics (BCYC) in Q4 2022, closing a stake of 24,033 shares — an estimated $559K sold.

Ensign Peak Advisors first reported a position in BCYC in Q4 2021 and held it in 4 quarters. The position peaked at $1.11M in Q4 2021. 87 funds tracked by Wall St. Rank hold BCYC as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Bicycle Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 24,033 Bicycle Therapeutics shares in Q4 2022, an estimated $559K.
  • Ensign Peak Advisors first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Bicycle Therapeutics position peaked at $1.11M in Q4 2021.
  • 87 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.